MX2020000785A - Metodos para la deteccion de discrasia de celulas plasmaticas. - Google Patents

Metodos para la deteccion de discrasia de celulas plasmaticas.

Info

Publication number
MX2020000785A
MX2020000785A MX2020000785A MX2020000785A MX2020000785A MX 2020000785 A MX2020000785 A MX 2020000785A MX 2020000785 A MX2020000785 A MX 2020000785A MX 2020000785 A MX2020000785 A MX 2020000785A MX 2020000785 A MX2020000785 A MX 2020000785A
Authority
MX
Mexico
Prior art keywords
methods
plasma cell
detection
cell dyscrasias
determining
Prior art date
Application number
MX2020000785A
Other languages
English (en)
Spanish (es)
Inventor
Mark Kidd
Irvin Mark Modlin
Ignat Drozdov
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Publication of MX2020000785A publication Critical patent/MX2020000785A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
MX2020000785A 2017-07-21 2018-07-18 Metodos para la deteccion de discrasia de celulas plasmaticas. MX2020000785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762535419P 2017-07-21 2017-07-21
PCT/US2018/042712 WO2019018540A1 (en) 2017-07-21 2018-07-18 METHODS FOR DETECTION OF PLASMOCYTE DYSGLOBULINEMIA

Publications (1)

Publication Number Publication Date
MX2020000785A true MX2020000785A (es) 2020-11-06

Family

ID=63244986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000785A MX2020000785A (es) 2017-07-21 2018-07-18 Metodos para la deteccion de discrasia de celulas plasmaticas.

Country Status (13)

Country Link
US (3) US20190025311A1 (enExample)
EP (1) EP3655553B1 (enExample)
JP (1) JP7223741B2 (enExample)
KR (1) KR102785072B1 (enExample)
CN (1) CN111194356B (enExample)
AU (1) AU2018304242B2 (enExample)
BR (1) BR112020000791A2 (enExample)
DK (1) DK3655553T3 (enExample)
ES (1) ES2916450T3 (enExample)
IL (1) IL271465B2 (enExample)
MX (1) MX2020000785A (enExample)
PL (1) PL3655553T3 (enExample)
WO (1) WO2019018540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000791A2 (pt) 2017-07-21 2020-07-21 Liquid Biopsy Research LLC métodos para detecção de discrasia de célula plasmática
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
CN111349705A (zh) * 2020-03-18 2020-06-30 昆明医科大学 circASXL1作为肺癌诊断标志物及其运用
AU2021281287A1 (en) * 2020-05-29 2023-01-19 Bio-Techne Corporation Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512557A (ja) 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
JP2004313167A (ja) 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用
EP1766086A4 (en) * 2004-05-21 2009-10-28 Univ Arkansas USE OF GENETIC EXPRESSION PROFILING TO PREVENT THE CHANCE OF SURVIVAL OF A PATIENT WITH CANCER
EP2687608B1 (en) 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
CN102361991A (zh) * 2009-01-02 2012-02-22 阿肯色大学托管委员会 硼替佐米在预测多发性骨髓瘤患者生存率中的应用
WO2011152884A2 (en) * 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) * 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma
BR112020000791A2 (pt) 2017-07-21 2020-07-21 Liquid Biopsy Research LLC métodos para detecção de discrasia de célula plasmática

Also Published As

Publication number Publication date
DK3655553T3 (da) 2022-06-20
US20260118360A1 (en) 2026-04-30
CN111194356A (zh) 2020-05-22
IL271465A (en) 2020-01-30
AU2018304242B2 (en) 2023-04-27
BR112020000791A2 (pt) 2020-07-21
JP2020528274A (ja) 2020-09-24
AU2018304242A1 (en) 2020-01-16
ES2916450T3 (es) 2022-07-01
WO2019018540A1 (en) 2019-01-24
IL271465B2 (en) 2023-08-01
KR20200029528A (ko) 2020-03-18
US20230022417A1 (en) 2023-01-26
EP3655553B1 (en) 2022-03-23
PL3655553T3 (pl) 2022-09-26
US12366575B2 (en) 2025-07-22
KR102785072B1 (ko) 2025-03-20
IL271465B1 (en) 2023-04-01
CA3067730A1 (en) 2019-01-24
US20190025311A1 (en) 2019-01-24
CN111194356B (zh) 2024-04-23
JP7223741B2 (ja) 2023-02-16
EP3655553A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
CL2018000649A1 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca
BR112015022763A8 (pt) sensor para detectar um analito
CL2017002604A1 (es) Sondas duales silenciadoras
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
MX2023000563A (es) Metodos y procesos para evaluacion no invasiva de variaciones geneticas.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
PL3060582T3 (pl) Testy do oznaczania biomarkerów układu kalikreiny osoczowej
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
EP4462120A3 (en) Methods for predicting response to parp inhibitors
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
IN2014DN04645A (enExample)
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
IL258637A (en) Immunoassay to detect cleaved high molecular weight kininogen
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
CL2014002211A1 (es) Sistema para determinar una propiedad de un objeto que comprende una disposicion de induccion para generar un impulso de fluido, un detector para detectar la vibracion fisical del objeto, un procesador acoplado al detector para determinar la propiedad del objeto; metodo para determinar una propiedad de un objeto; y una valvula.
BR112014024023A2 (pt) anticorpos idiotípicos anti-hcmv e usos dos mesmos
EA201690559A1 (ru) Способы определения ответа на терапию
BR112017021186A2 (pt) ?método para detectar a presença de bactérias produtoras de beta-lactamase?